Editorial: Game Changers in Inflammatory Bowel Diseases.
作者信息
Bálint Anita, Lovász Barbara Dorottya
机构信息
Department of Medicine, University of Szeged, Szeged, Hungary.
Faculty of Health Sciences, Institute of Applied Health Sciences, Semmelweis University, Budapest, Hungary.
出版信息
Front Med (Lausanne). 2021 Nov 18;8:795597. doi: 10.3389/fmed.2021.795597. eCollection 2021.
Abstract
摘要
相似文献
1
Editorial: Game Changers in Inflammatory Bowel Diseases.社论：炎症性肠病的变革者
Front Med (Lausanne). 2021 Nov 18;8:795597. doi: 10.3389/fmed.2021.795597. eCollection 2021.
2
Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.通过RAND方法评估炎症性肠病中免疫抑制药物的适用性：意大利炎症性肠病研究小组（IG-IBD）立场声明
Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013.
3
INTERACTIONS AMONG INTERLEUKIN-6, C-REACTIVE PROTEIN AND INTERLEUKIN-6 (-174) G/C POLYMORPHISM IN THE PATHOGENESIS OF CROHN'S DISEASE AND ULCERATIVE COLITIS.白细胞介素-6、C反应蛋白与白细胞介素-6（-174）G/C多态性在克罗恩病和溃疡性结肠炎发病机制中的相互作用
Acta Clin Croat. 2020 Mar;59(1):67-80. doi: 10.20471/acc.2020.59.01.09.
4
Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort.肥胖对炎症性肠病疾病活动和结局的影响：来自瑞士炎症性肠病队列的研究结果。
United European Gastroenterol J. 2020 Dec;8(10):1196-1207. doi: 10.1177/2050640620954556.
5
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.21 世纪全球炎症性肠病的发病率和流行率：基于人群的系统综述研究。
Lancet. 2017 Dec 23;390(10114):2769-2778. doi: 10.1016/S0140-6736(17)32448-0. Epub 2017 Oct 16.
6
7
Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease.主要组织相容性复合体基因在炎症性肠病易感性及疾病表型中的作用
Lancet. 1996 May 4;347(9010):1212-7. doi: 10.1016/s0140-6736(96)90734-5.
8
9
Identification of a prodromal period in Crohn's disease but not ulcerative colitis.克罗恩病前驱期的识别，但溃疡性结肠炎无此情况。
Am J Gastroenterol. 2000 Dec;95(12):3458-62. doi: 10.1111/j.1572-0241.2000.03361.x.
10
Familial occurrence and inheritance studies in inflammatory bowel disease.炎症性肠病的家族发病情况及遗传研究。
Neth J Med. 1996 Feb;48(2):53-6. doi: 10.1016/0300-2977(95)00093-3.
引用本文的文献
1
Effect and mechanism of total ginsenosides repairing SDS‑induced enteritis model based on MAPK pathway.基于MAPK通路的人参总皂苷修复SDS诱导的肠炎模型的作用及机制
Exp Ther Med. 2023 Jun 16;26(2):369. doi: 10.3892/etm.2023.12068. eCollection 2023 Aug.
本文引用的文献
1
Rediscovering histology: what is new in endoscopy for inflammatory bowel disease?重新认识组织学：炎症性肠病内镜检查的新进展有哪些？
Therap Adv Gastroenterol. 2021 Apr 16;14:17562848211005692. doi: 10.1177/17562848211005692. eCollection 2021.
2
An Introduction to Next Generation Sequencing Bioinformatic Analysis in Gut Microbiome Studies.肠道微生物组研究中下一代测序生物信息分析简介。
Biomolecules. 2021 Apr 2;11(4):530. doi: 10.3390/biom11040530.
3
An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians' Perspective.炎症性肠病新治疗选择对药理学家的最新进展：临床医生视角
Front Pharmacol. 2021 Apr 12;12:655054. doi: 10.3389/fphar.2021.655054. eCollection 2021.
4
Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?优化炎症性肠病的生物治疗：治疗药物监测有多重要？
Nat Rev Gastroenterol Hepatol. 2020 Nov;17(11):702-710. doi: 10.1038/s41575-020-0352-2. Epub 2020 Sep 2.
5
Serum Biomarkers for Inflammatory Bowel Disease.炎症性肠病的血清生物标志物
Front Med (Lausanne). 2020 Apr 22;7:123. doi: 10.3389/fmed.2020.00123. eCollection 2020.
6
Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients.口服抗肿瘤坏死因子域抗体 V565 可提供高肠道浓度，并降低溃疡性结肠炎患者的炎症标志物。
Sci Rep. 2019 Oct 1;9(1):14042. doi: 10.1038/s41598-019-50545-x.
7
Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease.新型生物标志物在炎症性肠病诊断中的新作用
World J Gastrointest Pharmacol Ther. 2016 Feb 6;7(1):41-50. doi: 10.4292/wjgpt.v7.i1.41.
Zotero 插件